World Library  
Flag as Inappropriate
Email this Article

Hypereosinophilic syndrome

Article Id: WHEBN0000893963
Reproduction Date:

Title: Hypereosinophilic syndrome  
Author: World Heritage Encyclopedia
Language: English
Subject: SIGLEC8, International Classification of Diseases for Oncology, List of cutaneous conditions, Outline of immunology, Loeffler endocarditis
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Hypereosinophilic syndrome

Hypereosinophilic syndrome
Classification and external resources
ICD-10 D72.1 (ILDS D72.12)
ICD-9-CM 288.3
ICD-O 9964/3
OMIM 607685
DiseasesDB 34939
eMedicine article/202030 article/1051555 article/886861
MeSH D017681

The hypereosinophilic syndrome (HES) is a disease characterized by a persistently elevated eosinophil count (≥ 1500 eosinophils/mm³) in the blood for at least six months without any recognizable cause, with involvement of either the heart, nervous system, or bone marrow.[1]

HES is a diagnosis of exclusion, after clonal eosinophilia (such as leukemia) and reactive eosinophilia (in response to infection, autoimmune disease, atopy, hypoadrenalism, tropical eosinophilia, or cancer) have been ruled out.[2]

There are some associations with chronic eosinophilic leukemia[3] as it shows similar characteristics and genetic defects.[4]

If left untreated, HES is progressively fatal. It is treated with glucocorticoids such as prednisone.[2] The addition of the monoclonal antibody mepolizumab may reduce the dose of glucocorticoids.[5]

Contents

  • Classification 1
  • Signs and symptoms 2
  • Diagnosis 3
  • Treatment 4
  • Epidemiology 5
  • References 6
  • External links 7

Classification

In the heart, there are two forms of the hypereosinophilic syndrome, endomyocardial fibrosis and Loeffler's endocarditis.

  • Endomyocardial fibrosis (also known as Davies disease) is seen in tropical areas.[6][7]
  • Loeffler's endocarditis does not have any geographic predisposition.

Signs and symptoms

As HES affects many organs at the same time, symptoms may be numerous. Some possible symptoms a patient may present with include:

Diagnosis

Numerous techniques are used to diagnose hypereosinophilic syndrome, of which the most important is blood testing. In HES, the eosinophil count is greater than 1.5 × 109/L.[4] On some smears the eosinophils may appear normal in appearance, but morphologic abnormalities, such as a lowering of granule numbers and size, can be observed.[4] Roughly 50% of patients with HES also have anaemia.[4]

Secondly, various imaging and diagnostic technological methods are utilised to detect defects to the heart and other organs, such as valvular dysfunction and arrhythmias by usage of echocardiography.[4] Chest radiographs may indicate pleural effusions and/or fibrosis,[4] and neurological tests such as CT scans can show strokes and increased cerebrospinal fluid pressure.[4]

A proportion of patients have a mutation involving the PDGFRA and FIP1L1 genes on the fourth chromosome, leading to a tyrosine kinase fusion protein. Testing for this mutation is now routine practice, as its presence indicates response to imatinib, a tyrosine kinase inhibitor.[8]

Treatment

Treatment primarily consists of reducing eosinophil levels and preventing further damage to organs.[4]

  • Hypereosinophilic Syndrome research in UK
  • Hypereosinophilic Syndrome on patient.info
  • Hypereosinophilic Syndrome on eMedicine
  • Hypereosinophilic Syndrome (HES) on American Academy of Allergy, Asthma & Immunology
  • Hypereosinophilic syndrome on Mayo Clinic
  • DermNet systemic/hypereosinophilic

External links

  1. ^ Chusid MJ, Dale DC, West BC, Wolff SM (1975). "The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature". Medicine (Baltimore) 54 (1): 1–27.  
  2. ^ a b Fazel R, Dhaliwal G, Saint S, Nallamothu BK (May 2009). "Clinical problem-solving. A red flag". N. Engl. J. Med. 360 (19): 2005–10.  
  3. ^ a b c d e f g h Longmore, Murray; Ian Wilkinson; Tom Turmezei; Chee Kay Cheung (2007). Oxford Handbook of Clinicial Medicine. Oxford. p. 316.  
  4. ^ a b c d e f g h i j k l m n o p Rothenberg, Marc E. "Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab". Retrieved 2008-03-17.  Last updated: Updated: Oct 4, 2009 by Venkata Samavedi and Emmanuel C Besa
  5. ^ a b c Rothenberg ME, Klion AD, Roufosse FE, et al. (March 2008). "Treatment of patients with the hypereosinophilic syndrome with mepolizumab". N. Engl. J. Med. 358 (12): 1215–28.  
  6. ^ Cotran, Ramzi S.; Kumar, Vinay; Fausto, Nelson; Nelso Fausto; Robbins, Stanley L.; Abbas, Abul K. (2005). Robbins and Cotran pathologic basis of disease. St. Louis, Mo: Elsevier Saunders. p. 606.  
  7. ^ Smedema JP, Winckels SK, Snoep G, Vainer J, Bekkers SC, Crijns HJ (December 2004). "Tropical endomyocardial fibrosis (Davies' disease): case report demonstrating the role of magnetic resonance imaging" (PDF). Int J Cardiovasc Imaging 20 (6): 517–22.  
  8. ^ Cools J, DeAngelo DJ, Gotlib J, et al. (2003). "A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome". N. Engl. J. Med. 348 (13): 1201–14.  

References

Patients who lack chronic heart failure and those who respond well to Prednisone or a similar drug have a good prognosis.[4] However, the mortality rate rises in patients with anaemia, chromosomal abnormalities or a very high white blood cell count.[4]

HES is very rare, with only 50 cases being noted and followed up in the United States between 1971 and 1982,[4] corresponding roughly to a prevalence of 1 to 2 per million people. The disease is even more uncommon within the paediatric population.[4]

Epidemiology

[5] If this becomes successful, it may be possible for corticosteroids to be eradicated and thus reduce the amount of side effects encountered.[5], may be treated with the monoclonal antibody Mepolizumab currently being developed to treat the disease.Churg-Strauss syndrome and asthma After promising results in drug trials (95% efficiency in reducing blood eosinophil count to acceptable levels) it is hoped that in the future hypereosinophilic syndrome, and diseases related to eosinophils such as [4] Follow-up care is vital for the survival of the patient, as such the patient should be checked for any signs of deterioration regularly.[4]

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.